ECM
NBIX icon

Everence Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Everence Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
3,074
+63
+2% +$9.35K 0.03% 410
2026
Q1 		$397K Buy
3,011
+211
+8% +$28K 0.02% 450
2025
Q4 		$397K Hold
2,800
– – 0.02% 471
2025
Q3 		$393K Hold
2,800
– – 0.02% 481
2025
Q2 		$352K Sell
2,800
-690
-20% -$79.1K 0.02% 509
2025
Q1 		$386K Hold
3,490
– – 0.03% 449
2024
Q4 		$476K Buy
+3,490
New +$432K 0.03% 378

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Everence Capital Management's NBIX Position: Q2 2026 in Review

Everence Capital Management increased its Neurocrine Biosciences (NBIX) stake by 2.1% in Q2 2026, buying an estimated $9.35K and bringing the position to 3,074 shares worth $518K. The position accounts for 0.03% of the portfolio, ranked #410.

Everence Capital Management first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Everence Capital Management held 3,074 shares of Neurocrine Biosciences worth $518K as of Q2 2026.
  • Everence Capital Management bought 63 Neurocrine Biosciences shares in Q2 2026, an estimated $9.35K.
  • Neurocrine Biosciences made up 0.03% of Everence Capital Management's portfolio in Q2 2026, its #410 holding.
  • Everence Capital Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.